Business
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Veteran CFO appointment underscores the Company’s commitment to building a strong leadership team as it advances its clinical and commercial strategyTEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financia
About this update from Nasus Pharma Ltd.
[{"type":"image","alt":"Nasus Pharma, Ltd.","displaySize":"","headline":null,"caption":"Nasus Pharma, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":241,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/quoV9o_G7y0qGuyE83dEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d","width":241,"height":136}},"lazy":false},{"type":"text","content":"Veteran CFO appointment underscores the Company’s commitment to building a strong leadership team as it advances its clinical and commercial strategy","length":149,"tagName":"p"},{"type":"text","content":"TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma’s executive leadership team.","length":554,"tagName":"p"},{"type":"text","content":"Mr. Rubin will lead and oversee Nasus Pharma’s financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the Company advances its pipeline of intranasal therapeutics towards achieving key clinical and commercial milestones.","length":281,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Eyal to our leadership team,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “We believe his deep financial expertise, strong command of capital markets, and successful track record of supporting clinical-stage and commercial-stage biotech companies make him the ideal addition to our leadership team as we enter an important phase of growth.”","length":384,"tagName":"p"},{"type":"text","content":"“We’re pleased to have Eyal join Nasus Pharma,” said Udi Gilboa, Executive Chairman of Nasus Pharma. “His extensive experience in both emerging biotechnology companies and commercial-stage pharmaceutical organizations will prove highly valuable to Na...